Marlise R. Luskin, MD, MSCE

SAN DIEGO — Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial.

SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.

SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute lymphoblastic leukemia.

Healio spoke with Marlise R. Luskin, MD, MSCE, a physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about tools that can be used to evaluate potential treatment response or relapse likelihood for patients with ALL.

Healio spoke with Marlise R. Luskin, MD, MSCE, a physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about the latest advances in our understanding of the molecular and genetic basis of ALL.

Healio spoke with Marlise R. Luskin, MD, MSCE, a physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about tools that can be used to evaluate potential treatment response or relapse likelihood for patients with ALL.

Healio spoke with Marlise R. Luskin, MD, MSCE, a physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about the unmet needs of patients with ALL.

Healio spoke with Marlise R. Luskin, MD, MSCE, a physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about the latest treatment options for ALL.

Healio spoke with Marlise R. Luskin, MD, MSCE, a physician at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, about treatment disparities in ALL care.